3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
8
Prostatic Neoplasms
7
Colorectal Neoplasms
4
Colorectal Neoplasms, Hereditary Nonpolyposis
3
Rectal Neoplasms
2
Ovarian Neoplasms
2
Neoplastic Syndromes, Hereditary
2
Colonic Neoplasms
2
Carcinoma, Intraductal, Noninfiltrating
2
Tuberous Sclerosis
1
Thyroid Neoplasms
1
Sarcoma
1
Pyloric Stenosis, Hypertrophic
1
Primary Ovarian Insufficiency
1
Polycystic Ovary Syndrome
1
Pheochromocytoma
1
Pediatric Solid Tumor
1
Paraganglioma
1
Pancreatic Neoplasms
1
Pancreatic Ductal Adenocarcinoma
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Melanoma
1
Lymphoproliferative Disorders
1
Lymphangioleiomyomatosis
1
Lipodystrophy, Familial Partial
1
Kidney Neoplasms
1
Histiocytosis, Non-Langerhans-Cell
1
Interventions
Trastuzumab
14
pertuzumab
10
Docetaxel
7
tucatinib
4
pyrotinib
4
Paclitaxel
4
Capecitabine
4
Carboplatin
2
Ado-Trastuzumab Emtansine
2
trastuzumab deruxtecan
1
pegfilgrastim
1
neratinib
1
exemestane
1
dalpiciclib
1
atezolizumab
1
Neoadjuvant Therapy
1
Leuprolide
1
Isovaleryl-CoA Dehydrogenase
1
Injections
1
Goserelin
1
Genetic Testing
1
Fulvestrant
1
Fluorodeoxyglucose F18
1
Blood Specimen Collection
1
Anastrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
HER2-positive Breast Cancer
×
Genetic Testing
×
1 year
×
Clear all
NCT04638725
2026-06-04
SIGHER
Centre Paul Strauss
Recruiting
9,000 enrolled